Davis's Drug Guide
mirvetuximab soravtansine
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
mir-ve-tux-i-mab soe-rav-tan-seen
Trade Name(s)
- Elahere
Ther. Class.
Pharm. Class.
drug-antibody conjugates
antimicrotubulars
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Mirvetuximab Soravtansine." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. www.drugguide.com/ddo/view/Davis-Drug-Guide/3580220/all/mirvetuximab_soravtansine.
Vallerand AHA, Sanoski CAC. Mirvetuximab soravtansine. Davis's Drug Guide. F.A. Davis Company; 2026. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580220/all/mirvetuximab_soravtansine. Accessed October 15, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Mirvetuximab soravtansine. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580220/all/mirvetuximab_soravtansine
Vallerand AHA, Sanoski CAC. Mirvetuximab Soravtansine [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 October 15]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580220/all/mirvetuximab_soravtansine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - mirvetuximab soravtansine
ID - 3580220
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/3580220/all/mirvetuximab_soravtansine
PB - F.A. Davis Company
ET - 20
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -